Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Search
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.